Priyadarshini Shista, Allison Derek B, Chauhan Aman
Internal Medicine, Guthrie Robert Packer Hospital, Sayre, PA 18840, USA.
Department of Pathology & Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA.
Pharmaceutics. 2022 Jul 1;14(7):1394. doi: 10.3390/pharmaceutics14071394.
Somatostatin receptors (SSTR) are expressed in various neoplasms and can be targeted for both diagnostics as well as therapeutics. This systematic review aims to compile and discuss the prevalence of somatostatin receptor expression in various neoplasms. We performed a literature search from Google Scholar and PubMed using relevant keywords to look for all publicly available data regarding SSTR expression in various cancers. Both histopathological and radiographical studies were included for SSTR assessment. We found that many cancers express SSTR with varying prevalence. SSTR is now a well-established theranostics biomarker. We now have highly sensitive and specific diagnostic modalities like gallium 68 DOTATATE and copper 64 DOTATATE scans to screen for SSTR-2 and then target it therapeutically with lutetium 177 DOTATATE. A thorough understanding of SSTR expression in other tumors will open the channels for exploring potential SSTR targeting.
生长抑素受体(SSTR)在多种肿瘤中表达,可作为诊断和治疗的靶点。本系统评价旨在汇总并讨论生长抑素受体在各种肿瘤中的表达情况。我们使用相关关键词在谷歌学术和PubMed上进行文献检索,以查找有关SSTR在各种癌症中表达的所有公开数据。纳入了用于SSTR评估的组织病理学和影像学研究。我们发现许多癌症以不同的发生率表达SSTR。SSTR现在是一种成熟的诊疗生物标志物。我们现在有像镓68 DOTATATE和铜64 DOTATATE扫描这样高度灵敏和特异的诊断方法来筛查SSTR-2,然后用镥177 DOTATATE进行靶向治疗。深入了解SSTR在其他肿瘤中的表达将为探索潜在的SSTR靶向开辟途径。